Page last updated: 2024-08-24

aromasil and Fracture, Pathologic

aromasil has been researched along with Fracture, Pathologic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T	1

Trials

1 trial(s) available for aromasil and Fracture, Pathologic

Article	Year
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. Journal of the National Cancer Institute, 2013, May-01, Volume: 105, Issue:9 Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome	2013

Article

Year

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

Journal of the National Cancer Institute, 2013, May-01, Volume: 105, Issue:9

Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome

2013